Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Italy Brings In New Measures In 2026 To Tackle Overtourism - 2Elvis Presley's Infamous Pantera Shooting
- 3Manual for Tracking down Spending plan Agreeable Travel Objections
- 4Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- 5Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- People who talk with their hands seem more clear and persuasive – new research
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- 5 Advancement Developments in Biotechnology
- The most effective method to Pick The Right Speakers
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
- Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
